Introduction
============

Glassy cell carcinoma (GCC) is a rare cancer originating in only 1% of cases in the uterine cervix.

Cervical GCC, a highly aggressive tumor characterized by resistance to radiation therapy, presents an unfavorable prognosis \[[@B1][@B2][@B3]\]. This malignancy has been considered as an uncommon variant of poorly differentiated adenosquamous carcinoma \[[@B1]\]. The first case of this condition was described by Cherry and Glucksmann \[[@B1]\] in 1956.

Rare cases of GCC arising in the fallopian tubes and colon have also been described in the literature \[[@B4][@B5]\].

Christopherson et al. \[[@B6]\] described the first case of endometrial GCC (EGCC) in 1982. EGCC is a very rare occurrence, and to the best of our knowledge, only 14 cases have been reported till date \[[@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13]\]. EGCC accounts for approximately 0.5% of all carcinomas in the endometrium \[[@B6]\] and is frequently considered as a variant of the adenosquamous endometrial carcinoma.

EGCC is a poorly differentiated neoplasm with little or no glandular or squamous differentiation. Microscopically the tumor cells have well-defined borders and a granular eosinophilic or amphophilic cytoplasm, imparting a ground glass appearance. The tumor cells are usually arranged in diffuse solid sheets and have large nuclei with prominent nucleoli \[[@B14]\]. The exact percentage of glassy cells for the diagnosis of GCC is not well established, and ranges from 30% to 100% \[[@B15]\].

The tumor could be positive for cytokeratin (CK) and carcinoembryonic antigen (CEA), even if available data are discordant in the description of the immunohistochemical characteristics of the neoplasm.

Given the rarity of EGCC, the challenges encountered in the diagnosis and the poor prognosis, we aimed to review the published literature on the condition. We have also reported a case of EGCC in a 64-year-old woman under regular follow-up and no signs of relapse of the disease, in order to contribute towards improvement of the clinical management of this tumor.

Case report
===========

A 64-year-old nulliparous patient underwent routine gynecological examination at the Seriate Bolognini Hospital in March 2017.

The patient was asymptomatic and reported a noncontributory familial and personal history. The gynecological examination was normal, while a routine Pap smear demonstrated positive results for adenocarcinoma. Subsequently, the patient underwent colposcopy, which was negative for signs of cervical carcinoma. She also underwent hysteroscopy, which revealed a tender and frail endometrial neoplasm with heavy atypical vascularization. A biopsy of the lesion was obtained, which was positive for EGCC. The specimen was found to be CK20, CD10, CEA, WT1, P63, estrogen and progesterone receptor-negative, while it was positive for AE1/AE3, CK7, P53, and P16.

Preoperative radiological investigations included chest X-ray, which was normal and pelvic magnetic resonance imaging that revealed a solid tumor completely occupying the uterine cavity and invading more than 50% of the myometrium. No other signs of disease were revealed. Blood test was normal, with negative tumor markers.

The patient underwent laparotomy; at the opening of the abdominal wall, we detected heavy, dense parieto-omental and utero-sigmoid adhesions. Peritoneal washing was collected. Lysis of the adhesions was performed to achieve optimal surgical exposure. Macroscopically, the uterus and the adnexa appeared normal; endoperitoneal and retroperitoneal surgical evaluation were negative, with no signs of the tumor.

Total hysterectomy and bilateral salpingo-oophorectomy were performed with pelvic lymphadenectomy and peritoneal and omental biopsies.

Conclusive pathological examination confirmed the initial diagnosis of EGCC involving 2 mm of myometrium (on a total thickness of 12 mm), International Federation of Gynecology and Obstetrics stage IA, grade 3. There were no signs of lymphovascular space invasion or presence of the disease in the blind peritoneal biopsies and the 18 pelvic nodes excised at the time of surgery.

Final immunoreaction test was comparable to the one performed during the first biopsy; the tumor was characterized by large cells with well-defined borders, granular eosinophilic or amphophilic cytoplasm, large nuclei and numerous mitotic cells. Heavy inflammatory cell infiltration was observed. These features were reported throughout the neoplasm ([Fig. 1](#F1){ref-type="fig"}).

![Hematoxylin and eosin staining (20×): Neoplasia characterized by ground glass cells with large nuclei associated with inflammatory cell infiltration.](ogs-62-478-g001){#F1}

In light of limited myometrial infiltration (under 50%), absence of lymphovascular space invasion, and the controversial utility of chemo-radiotherapy, the patient was referred to our outpatient clinic after surgery for clinical follow-up, which, until now (24 months), has not shown any evidence of relapse.

We obtained a written consent from the patient to collect and use her medical data for publication while maintaining anonymity.

Discussion
==========

GCC is a rare tumor, which usually originates from the cervix, but may occasionally arise in the fallopian tubes, endometrium, and colon \[[@B4][@B5]\].

The endometrial GCC accounts 0.5% of all carcinomas of the endometrium and, due to his rarity, few information was reported in literature about its pathogenesis. Cherry and Glucksmann \[[@B1]\] described the histological characteristics of the tumor as follows: moderate amount of cytoplasm, absence, or paucity of squamous or glandular differentiation, cell wall positivity for periodic acid Schiff and eosin, and large nuclei with prominent nucleoli. However, this pattern is not sufficient to trace the histogenesis of this uncommon tumor, which has traditionally been regarded, from the first description until today, as a poorly differentiated variant of adenosquamous carcinoma. Nevertheless, there is limited consensus regarding this hypothesis. Arends et al. \[[@B7]\] suggested that EGCC is not a true poorly differentiated tumor and do not consider the possibility that the condition is a variant of adenosquamous carcinoma. Furthermore, considering the absence of keratin and prekeratin and the presence of secretory component and lysozyme in the tumor cells, the group has supported an endocervical or isthmic origin of this neoplasia.

However, in the available literature, excluding the cases of advanced stages of the disease, EGCC were reported to be confined in the uterine corpus, suggesting that the hypothesis postulated by Arends et al. \[[@B7]\] is not accurate. Given the disagreement regarding the origin and histological diagnosis of this disease, systematic evaluation of the histological pattern is necessary to define strict and shared diagnostic criteria.

Considering the limited available information of this rare condition, we have summarized ([Table 1](#T1){ref-type="table"}) the reported cases and added the description of our patient.

###### Characteristics of patients with endometrial glassy cell carcinoma, therapy and follow up, as reported in the literature

![](ogs-62-478-i001)

  Author                            Age   Stage   Symptoms             Treatment              Follow-up
  --------------------------------- ----- ------- -------------------- ---------------------- --------------------------------------------
  Christopherson et al. \[[@B6]\]   56    I       Vaginal bleeding     RT+H                   DOD at 5 months
                                    70    I       Vaginal bleeding     RT+H                   DOD at 32 months
                                    71    I       Vaginal bleeding     RT+H                   Death of pneumonia after 6 years--NED
                                    78    I       Vaginal bleeding     RT                     Suicide after 7 months--no info on disease
                                    78    III     Vaginal bleeding     RT                     DOD after 5 months
  Arends et al. \[[@B7]\]           59    IIIA    Vaginal bleeding     TAHBSO+RT+Progestins   NED after 24 months
  Dawson et al. \[[@B8]\]           96    IVB     Vaginal bleeding     Megestrol              NED after 16 months
  De Rosa et al. \[[@B9]\]          58    IB      Metrorrhagia         TAHBSO                 DOD after 12 months
                                    52    IB      Metrorrhagia         TAHBSO+PND             DOD after 16 months
                                    58    IB      Metrorrhagia         TAHBSO+PND             ED after 36 months
  Hachisuga et al. \[[@B10]\]       62    IIIC    Vaginal bleeding     TAHBSO+PND+RT          NED after 66 months
  Mhawech et al. \[[@B11]\]         60    IB      Vaginal bleeding     TAHBSO+PND+RT          NED after 60 months
  Ferrandina et al. \[[@B12]\]      63    IB      Vaginal bleeding     TAHBSO+PND             NED after 69 months
  Nagy and Sipos \[[@B13]\]         68    IA                           TAHBSO+RT              NED after 24 months
  Current case                      64    IA      Abnormal pap smear   TAHBSO+PND             NED after 14 months

RT, radiotherapy; H, hysterectomy; TAHBSO, total abdominal hysterectomy bilateral salpingo-oophorectomy; PND, pelvic node dissection; DOD, death of disease; ED, alive with evidence of disease; NED, no evidence of disease.

The most frequent symptom at the time of admission was abnormal vaginal bleeding; and the age of the patients ranged from 52 to 96 years (mean, 66.2 years), in line with the diagnosis of classical endometrial cancer. Contrary to the cases reported in the literature, the incidental diagnosis of EGCC in our patient was made based on an abnormal pap smear in an asymptomatic woman. This incidental finding probably allowed earlier diagnosis of the neoplasm, which correlated with a non-metastatic tumor, and therefore, with a better prognostic outcome. There is no clear consensus for the management of EGCC, with hysterectomy often being the treatment of choice, occasionally associated with other treatments, such as radiation. As described in [Table 1](#T1){ref-type="table"}, 11 patients had stage I disease, 3 had stage III, and 1 presented with stage IV. The treatment was radiation followed by hysterectomy in 3 cases; radiation alone in 2 cases; hysterectomy and salpingo-oophorectomy alone in 1 case, in 1 case followed by radiation, in 6 cases associated with pelvic node dissection, of which 2 cases were followed by radiotherapy; 2 cases were treated with hormonal therapy, 1 alone and 1 in association with surgery and radiation. In 2 cases \[[@B7][@B8]\], hormonal therapy was the choice and the patients were treated successfully with hormonal therapy, suggesting the presence of, at least, progesterone receptors. In our case, similarly to those reported by Ferrandina et al. \[[@B12]\] and Mhawech et al. \[[@B11]\], estrogen and progesterone receptors were negative.

Few studies reported presence of hormonal receptors and performed immunohistochemical analysis. Ferrandina et al. \[[@B12]\] reported strong positivity for Ki67 and vascular endothelial growth factor, weak positivity for p53, Her2/Neu, and very weak positivity for bcl-2 protein, while estrogen and progesterone receptors were negative. Mhawech et al. \[[@B11]\] reported positivity for vimentin, neuron-specific enolase, protein gene product 9.5, p53, and Ki67, while chromogranin A and B, CEA, smooth muscle actin, muscle-specific actin, CAM 5.2, 34bE12, Leu-5, CK7, CK19, CK20, CK22, desmoplakin, desmin, myoglobin, human epidermal growth factor receptor 2 protein, and estrogen and progesterone receptors were negative.

Despite the fact that cervical GCC is known to be associated with poor prognosis; currently, the specific prognosis of EGCC remains unknown. Particularly, it is not possible to arrive at any conclusion considering the limited data available and the small sample size of the reported studies \[[@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13]\].

Follow-up period in the reported studies ranged from 5 to 69 months. In case of patients at stage I at the moment of surgery, 4 patients died of the disease within 16 months, while 2patients died due to other causes. In particular, one of these died after 6 years form surgery and no sign of endometrial cancer was detected at the autopsy. Four patients were alive with no evidence of the disease; and 1 patient was alive with the disease. Excluding one patient who committed suicide, 5 patients out of 11 (45.5%) were disease free (at minimum of 14 months). Regarding stage III, 2 patients out of 3 were alive without the disease (at 24 and 66 months), and the only patient with stage IV was alive after 16 months.

In conclusion, there is limited data pertaining to EGCC, with no standard guidelines to aid in therapeutic decision-making and counseling of patients.

We have therefore described a case of EGCC considering that, publication of more cases would aid in defining more strict and shared diagnostic criteria and better understand the course, ideal treatment, and accurate prognosis of this disease.
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